KONEXBiotech & Pharma229500

NovMetaPharma

₩3,880▼ 2.51%2026-11-18 close
Market Cap
₩50.4B
Turnover
₩5,646,520
Volume
1.5K
Shares out.
13M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Pipeline progress versus repeated dilution

With almost no product revenue, clinical progress and financing terms remain the key variables for NovMetaPharma.

  1. 1

    Revenue for 2025 fell to 34.84 million won, and with no marketed drug the company has a narrow revenue base.

  2. 2

    The 2025 net loss was 10.44 billion won, and the standalone operating loss was 5,367 million won.

  3. 3

    The debt ratio fell from 164.6% in 2024 to 21.4% in 2025, and total equity turned positive by the end of 2025.

  4. 4

    Two third-party share placements were made in 2026, with the issue price falling from 7,050 won per share in June to 3,120 won in November.

  5. 5

    Attempts to move to KOSDAQ since 2018 have failed four times, and the most recent SPAC merger was cancelled in May 2024 after the exchange withheld approval.

02

Business structure

NovMetaPharma, founded in 2010, is a metabolic-disease drug developer that listed on KONEX in October 2015.

It develops metabolic therapies based on novel mechanisms as well as kidney and muscle disease treatments, and it pursues a model in which licensing deals to global pharma generate milestone payments and royalties.

Its core pipeline includes NovDB2 for type 2 diabetes and NovOB for obesity, both of which have completed Phase 2b trials in the United States and are in Phase 2c.

NovDKD for diabetic kidney disease is in a Phase 2 trial in Korea, and NovFS-IP for idiopathic pulmonary fibrosis received FDA Orphan Drug Designation in May 2024. Combination trials of the sarcopenia candidate CZ with Novo Nordisk's Wegovy have been discussed, according to press reports.

No drug is currently on the market, and revenue has come mainly from raw materials and health functional foods. In obesity, GLP-1 drugs such as Wegovy serve as the reference point, and the company points to combination use and licensing potential as its differentiators.

According to Research and Markets, the IPF treatment market is projected to reach 6.1 billion dollars by 2030, growing about 7% a year. A 2024 press report said development of a C01-based skin booster had been completed.

03

Recent trends

Reported results show a very small revenue base and continuing operating and net losses. According to the 2025 business report, revenue was 34.84 million won and net loss was 10.44 billion won. On a standalone basis, the 2025 operating loss was 5,367 million won and the net loss was 10,447 million won.

Total equity at the end of 2025 stood at 3,593 million won, and the debt ratio fell from 164.6% in 2024 to 21.4%. Revenue rose to 45.31 million won in 2024 from 13.85 million won in 2023, but it declined again in 2025. The 2024 operating loss was 5.54 billion won, slightly smaller than in 2023.

Total equity had fallen to negative 4.2 billion won at the end of 2022. Financing continued in 2026: the board resolved on June 17, 2026 to issue 158,862 shares at 7,050 won each to raise 1.12 billion won.

On November 6, 2026, a third-party placement of 246,787 shares at 3,120 won each, raising 770 million won, was disclosed. As of the October 29, 2026 intraday quote, the share price was 3,410 won, with a 52-week high of 15,600 won and a low of 3,295 won, and the 12-month return was negative 74.74%.

04

Outlook

The key variable for future results is whether the revenue mix shifts from raw materials and health functional foods toward licensing income. With 2025 revenue at 34.84 million won, operating results depend largely on the scale of clinical development spending.

Disclosures of Phase 2c results for NovDB2 and NovOB, and of Phase 2 progress for NovDKD, could change how the pipeline is valued. No licensing agreement has yet been reflected in reported results.

On financing, the November 6, 2026 placement sets payment for November 16 and listing of the new shares for December 4, so the share count will keep rising. With more shares outstanding, per-share metrics should be read on a diluted basis.

On the listing route, the 2024 SPAC merger was cancelled after exchange non-approval, and the company said it would seek relisting, though press reports said the method had not been decided. As of 2024, none of its drugs had completed Phase 3.

05

Bull factors

Diversified clinical pipeline

NovDB2 and NovOB have completed Phase 2b trials in the United States and are now in Phase 2c, while NovDKD is in a Phase 2 trial in Korea. NovFS-IP received FDA Orphan Drug Designation in May 2024. A candidate set spanning metabolic, fibrotic and muscle diseases could widen the range of licensing discussions.

Strengthened leadership and advisory bench

Press reports in early 2025 said a proposal to appoint Stuart Peltz, former CEO of PTC Therapeutics, as an inside director was tabled, and that he would lead overseas business. A former chief commercialization officer with rare-disease launch experience was also reported to be joining. The company said these hires strengthen its work on muscle disease therapies and commercialization.

Equity recovery and lower leverage

The debt ratio fell from 164.6% in 2024 to 21.4% in 2025. After total equity had dropped to negative 4.2 billion won at the end of 2022, it stood at 3,593 million won at the end of 2025. Press reports attributed the recapitalization to rights offerings and conversion of convertible bonds into common shares.

06

Bear factors

Thin revenue base

Revenue for 2025 declined from the prior year to 34.84 million won. Standalone operating loss for the same year was 5,367 million won, and net loss was 10,447 million won. With no marketed drug, the company has limited sources of revenue to offset operating losses. A 2024 press report said none of its pipeline drugs had completed Phase 3.

Frequent placements and dilution

The new shares the board resolved to issue in June 2026 reduce the ownership percentages of existing shareholders. The third-party placement disclosed on November 6, 2026 involves 246,787 shares at 3,120 won each, raising 770 million won.

The issue price fell sharply between the two deals, and the 12-month return stood at negative 74.74% on the October 29, 2026 intraday quote.

Stalled move to KOSDAQ

NovMetaPharma has pursued a move to KOSDAQ four times since 2018 without success. In May 2024, its SPAC merger with SK Securities' No. 8 SPAC was cancelled after the exchange withheld approval. The company said it would seek relisting, but press reports said the route had not been decided.

07

Risk factors

Macro

Changes in interest rates and investor sentiment toward biotech directly affect financing conditions for small KONEX-listed biotech companies. Equity raises depend heavily on market prices and issue levels. The won value of any overseas licensing payments also moves with exchange rates.

Clinical and regulatory

If Phase 2c results for NovDB2 and NovOB or Phase 2 results for NovDKD fall short, the pipeline's value could be reduced. Changes in trial design requirements from the US FDA or Korea's MFDS could delay timelines. With no drug having completed Phase 3, late-stage development costs remain a burden.

Financing and listing

Because revenue is small and cash generation from operations is limited, the company relies on equity placements and convertible bonds. Rising share counts dilute value per share. Trading liquidity on KONEX can be thin, and financial requirements could again become an obstacle in any KOSDAQ listing review.

08

Overall view

NovMetaPharma has almost no product revenue, so its business value rests largely on how its clinical pipeline progresses. Bullish factors include the Phase 2c programs for NovDB2 and NovOB, the Phase 2 trial of NovDKD, and FDA Orphan Drug Designation for NovFS-IP, alongside a restored equity position.

Bearish factors include 2025 revenue of 34.84 million won, a net loss of about 10.4 billion won, and dilution from back-to-back third-party placements in 2026. The drop in the November 2026 issue price to 3,120 won and the 12-month return of negative 74.74% show how financing terms have shifted.

On listing, four attempts to move to KOSDAQ have failed, and the most recent SPAC merger was cancelled after non-approval. Until clinical results or licensing agreements show up in reported results, the financial structure and financing flows will remain the main variables in assessing the company.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. comp.fnguide.com
  2. alphasquare.co.kr
  3. m.news.nate.com
  4. greened.kr
  5. vegannews.co.kr
  6. markets.hankyung.com
  7. m.ekn.kr
  8. hitnews.co.kr
  9. dailymedi.com
  10. pharm.edaily.co.kr
  11. pharm.edaily.co.kr
  12. saramin.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis